Early clinical progress on a novel heart-failure therapy: this upbeat article previews the study's design, safety goals, and the company's development plans.
Key Takeaways
- We are open to conversations with prospective partners and investors who share our vision
- Investigational antisense oligonucleotide that targets the WISPER long non-coding RNA
- HTX-001 remains investigational and is not approved by the U.S